Short Interest in iBio, Inc. (NYSEAMERICAN:IBIO) Rises By 27.6%

iBio, Inc. (NYSEAMERICAN:IBIO) saw a large growth in short interest in January. As of January 15th, there was short interest totalling 242,000 shares, a growth of 27.6% from the December 31st total of 189,700 shares. Based on an average daily trading volume, of 140,200 shares, the days-to-cover ratio is currently 1.7 days. Currently, 2.7% of the shares of the stock are short sold.

iBio Stock Up 1.3 %

Shares of NYSEAMERICAN IBIO traded up $0.04 during midday trading on Friday, reaching $3.01. The company’s stock had a trading volume of 241,595 shares, compared to its average volume of 266,153. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.04. iBio has a one year low of $1.05 and a one year high of $4.98.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.